SYSTEM UPDATES
recent changes
july 2026
Ontario Health’s Comprehensive Cancer Biomarker Testing Program list of funded tests and testing sites was updated, effective july 1, 2026. new additions include CLDN 18.2 for gastric cancer, a pancreatic cancer panel and mismatch repair testing for any progressed solid tumour.
Ontario Health (Cancer Care Ontario)
june 2026
the updated State of Readiness report finds canada only partially ready for genomic medicine. Alberta and Newfoundland and Labrador are best prepared; Ontario made the most progress since 2023; only Québec has an established funding formula for new tests. the study was industry-funded.
Husereau et al., Current Oncology
march 2025
an environmental scan was conducted to identify and synthesize existing information related to frameworks and processes that currently inform the assessment, implementation, and funding decisions for genetic and genomic biomarker testing as well as what biomarker testing is currently available or being funded in cancer care across Canada.
Canada's Drug Agency
reports, research and guidance
THE LIBRARY
from researchers, agencies, governments, clinicians and colab.
Biomarqueurs tumoraux liés à la prise en charge des personnes atteintes d'une tumeur solide (tumour biomarkers for solid tumours)
INESSS · updated august 2026 · français
providers, decision makers
for
Environmental Scan of Genetic and Genomic Biomarker Testing Assessment Frameworks, Processes, and Inventories in Cancer Care
Canada’s Drug Agency · Canadian Journal of Health Technologies · 2025
decision makers, industry
for
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2− Metastatic Breast Cancer 2025
Jerzak et al. · Breast Cancer Canada · Current Oncology · 2026
providers, advocates
for
Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2026)
ESMO
providers
for
CCC Skin Cancer Pathway Map
cancer care ontario
providers
for
ESMO Recommendations on clinical reporting of genomics test results for solid cancers (Nov 2024)
ESMO
providers, decision makers
for
Assessment Framework for Biomarkers Used in Cancer Care
Canada’s Drug Agency · april 2026
decision makers, industry, providers
for
Ontario Genetic Test Directory
Ontario Health
providers
for
Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada
conference report · Current Oncology · 2024
providers, decision makers
for
A Comparison of Patients’ and Physicians’ Knowledge and Expectations Regarding Precision Oncology Tests
peer-reviewed study
providers, advocates
for
Draft framework for assessing cancer biomarker tests (consultation)
Canada’s Drug Agency · 2025
decision makers, industry
for
Genetic testing resources for health care providers
Ontario Health (Cancer Care Ontario)
providers
for
Profilage moléculaire de l'ADN tumoral circulant à partir d'une biopsie liquide : cancer du sein (ctDNA profiling for breast cancer)
INESSS · june 2026 · français
decision makers, providers
for
Accelerating equitable cancer genomics and precision oncology in health care and research: a Lancet Oncology Commission
Casolino et al. · The Lancet Oncology · 2026
decision makers, advocates
for
Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma
Brezden-Masley et al. · Current Oncology · 2024
providers
for
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2026)
ESMO
providers
for
CCC Breast Cancer Pathway Map
cancer care ontario
providers
for
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group (Feb 2025)
ESMO
providers
for
Plasma Based Comprehensive Genomic Profiling DNA Assays for Non-Small Cell Lung Cancer: recommendation
Ontario Health · november 2024
decision makers, providers
for
Progress toward Health System Readiness for Genome Based Testing in Canada
Husereau et al. · Current Oncology · 2023
decision makers, industry
for
Implementation of Liquid Biopsy in Non Small Cell Lung Cancer: An Ontario Perspective
Breadner et al. · Current Oncology · 2024
providers, decision makers
for
Comprehensive Cancer Biomarker Testing Program: funded tests and testing sites
Ontario Health (Cancer Care Ontario) · as of july 1, 2026
providers, advocates
for
Proposed enhancements to drug reimbursement reviews, including testing procedure assessments
Canada’s Drug Agency · 2026
industry, decision makers
for
ASCO 2026: testing dependent therapies and what Canada needs in place
the cancer collaborative · 2026
decision-makers, industry
for
Politique québécoise en médecine génomique (Québec genomic medicine policy)
Gouvernement du Québec · june 2026 · français
decision makers, industry, advocates
for
Precision medicine: a pathway to targeted, personalized and equitable care (World Health Assembly resolution)
World Health Organization · may 2026
decision makers
for
Strengthening Biomarker Research in Canadian Cancer Clinical Trials: A Pathology-Focused White Paper
Schaeffer et al. · CCTG Pathology Working Group · Current Oncology · 2026
providers, decision makers
for
CCC pathway maps
cancer care ontario
providers
for
CCC Lung Cancer Pathway Map
cancer care ontario
providers
for
Readiness to Consider and Adopt Genetic and Genomic Tests in Canada: An Update to the State of Readiness Report
Husereau et al. · Current Oncology · 2026
decision makers, industry
for
Provincial Laboratory Formulary
Government of Newfoundland and Labrador
providers, industry
for
Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada
conference report · Current Oncology · 2025
providers, decision makers
for
Exploring Cancer Patients’ and Caregivers’ Perspectives and Knowledge Regarding Biomarker Testing in Canada
Current Oncology · 2025
advocates, providers
for
Biopsies liquides : avis (liquid biopsy recommendation)
INESSS · august 2024 · français
decision makers, providers
for
Environmental scan: pharmaceuticals requiring companion diagnostics
CADTH (now Canada’s Drug Agency)
industry, decision makers
for
colab | #KNOWvember
independent, non promotional information on precision oncology and biomarker testing in canada, from the cancer collaborative | le collaboratoire cancer. reviewed and refreshed every year.
explore
for industry
.png)